VITRUVIAN BIO, LLC — Department of Health and Human Services SBIR Phase I: 103
VITRUVIAN BIO, LLC — SBIR Phase I award from Department of Health and Human Services.
- Amount
- $300,000
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- SBIR · Phase I
- Topic
- 103
- Solicitation
- PHS-2022-1
- NAICS
- —
- Place of performance
- MD
- Period
- —
Description
Development of Diagnostics to Differentiate HIV Infection from Vaccine Induced Seropositivity: Several years of clinical trials have revealed that some HIV vaccines can elicit long-lasting (rt15 years) serological immune responses that can be confused with HIV infection in common diagnostic tests. This phenomenon is known as vaccine-induced sero-reactivity or sero-positivity (VISR/VISP). The overarching goal of this program is to support the development of new serological and nucleic acid assays that can identify HIV infection while avoiding false-positive results due to VISP, with high sensitivity and specificity.